> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Abbott Expanded Indication for Ablation Catheter
- URL: https://www.fdaweb.com/abbott-expanded-indication-for-ablation-catheter/
- Published: 2023-02-06T12:00:00.000Z
- Updated: 2026-09-14T18:14:42.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5153707

FDA has approved an Abbott expanded indication for its [FlexAbility Ablation Catheter, Sensor Enabled,](https://www.cardiovascular.abbott/us/en/hcp/products/electrophysiology/ablation-technology/flexability-se-ablation-catheter.html?ref=fdaweb.com) a flexible tip catheter intended to help physicians identify abnormal signals and apply therapy to treat ventricular tachycardia (VT) in patients with non-ischemic cardiomyopathy (NICM). The company says NICM is a type of heart muscle disease that prevents blood from being adequately pumped from the heart, which can lead to VT, a fast heart rhythm that can cause cardiac arrest if untreated. “Procedures to treat these patients are considered complex due to the nature of the disease itself and the need to treat both inside and outside surfaces of the heart,” Abbott says.

The expanded approval was based on Abbott’s LESS-VT study, which the company describes as the first FDA-approved pre-market trial to assess ablation for treating VT with an NICM origin. The study showed that 80% of study patients treated with Flexibility were free from VT for at least six months post-procedure. “The data also showed statistically significant improvements in patients’ mental and physical quality-of-life measures,” the company says.